CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Teriparatide (rDNA origin) injection

Last Updated: October 23, 2009
Result type: Reports
Project Number: SR0180-000
Product Line: Reimbursement Review

Generic Name: Teriparatide (rDNA origin) injection

Brand Name: Forteo

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Osteoporosis (in women), Severe

Indications: Osteoporosis (in women), Severe

Submission Type: Drug Plan Initiated

Project Status: Complete

Date Recommendation Issued: March 17, 2010

Recommendation Type: Do not list